Abbott Laboratories Announces Partnership with Velcera to Bring New Pain Medication for Dogs to Market

ABBOTT PARK, Ill., Aug. 18 /PRNewswire/ -- Abbott announced today they have partnered with Velcera, Inc., a specialty pharmaceutical company focused on pet health, to market the first canine pain management product delivered in a transmucosal mist form. Currently in clinical trials, the product combines the proven pain medication meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with Velcera's patented Promist(TM) technology, and has been globally licensed for pain management in dogs.